iifl-logo

Healthcare Sector

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Karvy Customer: For activating your account click here.
Download App
image

The company's board of directors will meet on Tuesday, May 7, 2024, to consider and approve the audited standalone and consolidated financial results.

image

The pharmaceutical stock was offered on public markets in May of last year, at a 20% premium to its issue price of ₹1,080.

image

Rodolfo Hrosz, Managing Director of Sanofi India Limited, emphasized that their CNS products hold leading positions within their respective categories.

image

He will be located in Mumbai and would be in charge of Lupin's technical operations.

image

Indranil Sen has resigned to seek possibilities outside of the organisation.

image

As part of the agreement, around 430 people from the company are scheduled to migrate to Eris.

image

Against its annual contracted value of USD50m supplies for Librela, Syngene has supplied USD94m worth of Librela to Zoetis over the past 13 months, which likely implies that Librela supplies to Zoetis will continue to taper off in CY24 and will present a tough base for Syngene going ahead. Syngene shipped just USD2m worth of Librela in Feb’24 vs USD21/13m in Dec’23/Jan’24 respectively.

image

The settlement agreement opens the door for Yesafili, a planned biosimilar of Eeylea (aflibercept) injection, to be sold in Canada.

image

Apollo Hospitals, KIMS, and Fortis Healthcare all declined about 2%.

image

This approval adds to Strides' list of products in the HIV treatment category through the PEPFAR pathway, totaling 15 products

Download App
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2026, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

ISO certification icon
We are ISO/IEC 27001:2022 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.